Does thyroid surgery for Graves' disease improve health-related quality of life?

Surgery Today

Volumn 43, Issue 12, 2013, Pages 1398-1405

  Scerrino, Gregorio ^a   Morfino, Giuditta ^a   Paladino, Nunzia Cinzia ^a   Paola, Valentina Di ^a   Amodio, Emanuele ^a   Gulotta, Gaspare ^a   Bonventre, Sebastiano ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Graves' disease; Quality of life; Questionnaire; Total thyroidectomy

Indexed keywords

ANTITHYROID AGENT; THYROTROPIN RECEPTOR ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANXIETY; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BODY WEIGHT; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; EXOPHTHALMOS; FEMALE; GRAVES DISEASE; HUMAN; HYPOCALCEMIA; HYPOTHYROIDISM; INSOMNIA; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIGRAINE; NEUROLOGIC DISEASE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PSYCHOSOCIAL DISORDER; QUALITY OF LIFE; QUESTIONNAIRE; RETROSPECTIVE STUDY; SOCIAL ISOLATION; STRESS; SUBCLINICAL HYPOTHYROIDISM; SUBSTITUTION THERAPY; SWEATING; THYROIDECTOMY; TREATMENT FAILURE;

ACTIVITIES OF DAILY LIVING; ADULT; FEMALE; GRAVES DISEASE; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; QUALITY OF LIFE; QUESTIONNAIRES; RETROSPECTIVE STUDIES; THYROIDECTOMY;

EID: 84892370916     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-012-0442-z     Document Type: Article

References (29)

1. Heemstra KA, Smit JWA. Advances in the treatment of Graves' disease-a focus on Rituximab. Eur Endocrinol. 2008;4(II).
2. Watt T, Groenvold M, Rasmussen AK, Bonnema SJ, Hegedüs L, Bjorner JB, et al. Quality of life in patients with benign thyroid disorders. A review. Eur J Endocrinol. 2006;154:501-10.
3. Elberling TV, Rasmussen AK, Feldt-Rasmussen U, Hørding M, Perrild H, Waldemar G. Impaired health-related quality of life in Graves' disease. A prospective study. Eur J Endocrinol. 2004; 151:549-55.
4. Ladenson PW. Psychological well-being in patients. Clin Endocrinol. 2002;57:575-6.
5. Chris M, Bruns CM, Chen H. The surgical management of Graves' disease. J Surg Res. 2006;133:207-14.
6. Boostrom S, Richards ML. TT is the preferred treatment for patients with Graves' disease and a thyroid nodule. Otolaryngol Head Neck Surg. 2007;136:278-81.
7. Cooper DS. Antithyroid drugs. N Engl J Med. 2005;352(9): 905-17.
8. Palit TK, Miller CC 3rd, Miltenburg DM. The efficacy of thyroidectomy for Graves' disease. A meta-analysis. J Surg Res. 2000;90(2):161-5.
9. Weber KJ, Solorzano CC, Lee JK, Gaffud MJ, Prinz RA. Thyroidectomy remains an effective treatment option for Graves' disease. Am J Surg. 2006;191(3):400-5.
10. Al-Adhami A, Craig W, Krukowski ZH. Quality of life after surgery for Graves' disease: comparison of those having surgery intended to preserve thyroid function with those having ablative surgery. Thyroid. 2012;22(5):494-500. (Epub 2012 Mar 15).
11. Cawood T, Moriartry P, O'Shea D. Recent developments in thyroid eye disease. BMJ. 2004;329:385-90.
12. Estcourt S, Quinn AG, Vaidya B. Quality of life in thyroid eye disease: impact of quality of care. Eur J Endocrinol. 2011; 164:649-55.
13. Gerding MN, Terwee CB, Dekker FW, Koornneef L, Prummel MF, Wiersinga WM. Quality of life in patients with Graves' ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument. Thyroid. 1997;7:885-9.
14. Kahaly GJ. Psychological morbidity of Graves' orbitopathy. Clin Endocrinol. 2005;103:368-411.
15. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990; 199-208.
16. Bradley EA, Sloan JA, Novotny PJ, Garrity JA, Woog JJ, West SK. Evaluation of the national Eye Institute Visual Function Questionnaire in Graves' ophthalmopathy. Ophthalmology. 2006;113:1450-4.
17. Farid M, Roch-Levecq AC, Levi L, Brody BL, Granet DB, Kikkawa DO. Psychological disturbance in Graves' ophthalmopathy. Arch Ophthalmol. 2005;123:491-6.
18. Terwee CB. Long-term effects of Graves' ophthalmopathy on health-related quality of life. Eur J Endocrinol. 2002;146:751-7.
19. R Development Core Team. R statistical software package, version 2.2.0, 2005. Available at: http://www.r-project.org.
20. Takamura Y, Nakano K, Uruno T, Ito Y, Miya A, Kobayashi K, et al. Changes in serum TSH receptor antibody (TRAb) values in patients with Graves' disease after total or subtotal thyroidectomy. Endocr J. 2003;50(5):595-601.
21. Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Tørring O. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol. 2008;158(1):69-75.
22. Schüssler-Fiorenza CM, Bruns CM, Chen H. The surgical management of GD. J Surg Res. 2006;133(2):207-14. (Epub 2006 Feb 3).
23. Kashiwai T, Hidaka Y, Takano T, Tatsumi KI, Izumi Y, Shimaoka Y, Tada H, Takeoka K, Amino N. Practical treatment with minimum maintenance dose of anti-thyroid drugs for prediction of remission in Graves' disease. Endocr J. 2003;50(1):45-9.
24. Weetman AP. Controversy in thyroid disease [comment] [Review; 44 refs]. J R Coll Physicians Lond. 2000;34:374.
25. Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves' ophthalmopathy. Thyroid. 2002;12:855-60.
26. Whybrow PC, Bauer M. Behavioral and psychiatric aspects of thyrotoxicosis. In: Braverman LE, Utiger RD, editors. Werner & Ingbar's the thyroid: a fundamental and clinical text. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 673-8.
27. Benevicius R, Velickiene D, Prange AJ Jr. Mood and anxiety disorders in women with treated hyperthyroidism and ophthalmopathy caused by Graves' disease. Gen Hosp Psychiatry. 2005;27:133-9.
28. Coulter I, Frewin S, Krassas GE, Perros P. Psychological implication of Graves' orbitopathy. Eur J Endocrinol. 2007;157: 127-31.
29. Nieuwkerk PT, Tollenaar MS, Oort FJ, Sprangers MA. Are retrospective measures of change in quality of life more valid than prospective measures? Med Care. 2007;45(3):199-205.